NASDAQ:FULC

Fulcrum Therapeutics Q2 2025 Earnings Results & Report

Fulcrum Therapeutics logo
$3.74 +0.02 (+0.40%)
As of 11:16 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Fulcrum Therapeutics beat analyst earnings expectations in its Q2 2025 results, released July 29, 2025. The company reported EPS of -$0.28 versus the -$0.29 consensus estimate.

Earnings Announcement Details

Quarter
Q2 2025
Report Date
Time
Before Market Opens
Conference Call
4:00 PM ET

Fulcrum Therapeutics EPS Results

Actual EPS
-$0.28
Consensus EPS
-$0.29
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 8 quarters

Fulcrum Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Fulcrum Therapeutics Q2 2025 Earnings FAQ

Fulcrum Therapeutics (NASDAQ:FULC) reported earnings of -$0.28 per share for Q2 2025, beating the consensus estimate of -$0.29. The report was announced on Tuesday, July 29, 2025.

Fulcrum Therapeutics Earnings Headlines

Fulcrum Therapeutics (NASDAQ:FULC) Upgraded at Wall Street Zen
Top Trader Reveals Stunning Black Friday Deal
Others paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Trading's Thomas Wood calls it one of the firm's most powerful proprietary trading indicators, and says the company has never run a deal like this before. There are no strings attached, just a steep Black Friday discount on a tool built for traders.tc pixel
See More Fulcrum Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Fulcrum Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Fulcrum Therapeutics and other key companies, straight to your email.

About Fulcrum Therapeutics

Fulcrum Therapeutics (NASDAQ:FULC) is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts. It develops medicines for genetically defined diseases, with research focused on changing gene expression to address the underlying causes of illness.

The company’s work has included programs for sickle cell disease and facioscapulohumeral muscular dystrophy, a rare genetic muscle disorder. Its research has explored approaches such as influencing hemoglobin production and modifying disease-related gene activity.

Founded in 2016, Fulcrum conducts drug discovery and development primarily in the United States. Its programs and development priorities may change as clinical research progresses.

View Fulcrum Therapeutics Profile